Key Highlights
- Net loss per share was USD 0.43 against an estimate of a USD 0.79 loss.
- Net loss was USD 38.30 million, compared with USD 20.28 million.
- Research and development expense was USD 34.50 million, compared with USD 15.70 million.
- Cash and cash equivalents were USD 90.22 million at September 30, 2026.
Lexeo Therapeutics (NASDAQ:LXEO) reported a net loss of USD 38.30 million for the third quarter of 2026, compared with a net loss of USD 20.28 million in the third quarter of 2025. The net loss per share was USD 0.43, compared with USD 0.33, against an estimate of a USD 0.79 loss.
The Quarterly Report did not state a Revenue figure for the period.
Operating Expenses
Research and development expense was USD 34.50 million, compared with USD 15.70 million in the prior-year quarter. General and administrative expense was USD 5.90 million, compared with USD 5.95 million. Total operating expenses, which equal the loss from operations, were USD 40.40 million, compared with USD 21.65 million.
Interest income was USD 2.16 million, compared with USD 1.46 million.
Nine-Month Results
For the nine months ended September 30, 2026, the net loss was USD 84.36 million, compared with USD 79.04 million, and the net loss per share was USD 0.99, compared with USD 1.72. Research and Development expense for the nine months was USD 69.23 million, compared with USD 47.59 million, and general and administrative expense was USD 21.53 million, compared with USD 38.55 million. Total operating expenses for the nine months were USD 90.75 million, compared with USD 86.14 million.
Cash and Investments
Cash and cash equivalents were USD 90.22 million at September 30, 2026, compared with USD 63.00 million at December 31, 2025. The current portion of investments in U.S. Treasury securities was USD 104.56 million, compared with USD 118.77 million. Prepaid expenses and other current Assets were USD 10.15 million, compared with USD 6.63 million, and total current assets were USD 204.93 million, compared with USD 188.39 million.
The filing reports 82,788,599 shares of common stock outstanding as of November 12, 2026. The company states that its cash and U.S. Treasury securities of USD 219.1 million are sufficient to fund its operations for at least 12 months from the issuance date of the financial statements, that its accumulated Deficit was USD 464.5 million, and that it anticipates substantial operating losses and negative cash flows from operations for the foreseeable future.
On March 24, 2025, the company entered into a sales agreement with Leerink Partners to sell shares of common stock having an aggregate offering price of up to USD 75.0 million through an at-the-market Equity offering program. The company describes LX2006 for the treatment of Friedreich's ataxia cardiomyopathy as its most advanced cardiovascular product candidate, and states that it acquired four in-process research and development assets from Mantle related to Friedreich's ataxia programs. In October 2025, it provided an interim clinical update covering 17 treated participants across two studies.
Lexeo Therapeutics Q3 2026 Earnings: Key Takeaways
Lexeo Therapeutics reported a third quarter 2026 net loss of USD 38.30 million and a loss per share of USD 0.43. Cash and cash equivalents were USD 90.22 million at September 30, 2026.






Please wait processing your request...